Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jan 24, 2022; 13(1): 28-38
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.28
Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma
Maja Popovic, Gorana Matovina-Brko, Masa Jovic, Lazar S Popovic
Maja Popovic, Gorana Matovina-Brko, Masa Jovic, Lazar S Popovic, Department of Medical Oncology, Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica 21204, Serbia
Maja Popovic, Lazar S Popovic, Faculty of Medicine, University of Novi Sad, Novi Sad 21000, Serbia
Author contributions: Maja P, Gorana MB, Masa J and Lazar SP designed the research; Maja P, Gorana MB, Masa J and Lazar SP performed the research; Maja P and Lazar SP contributed analytic tools; Maja P, Gorana MB, Masa J and Lazar SP analyzed the data; Maja P wrote the paper.
Conflict-of-interest statement: Authors declare no conflict on interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lazar S Popovic, MD, PhD, Professor, Department of Medical Oncology, Oncology Institute of Vojvodina, Faculty of Medicine, University of Novi Sad, Put dr Goldmana 4, Sremska Kamenica 21204, Serbia. lazar.popovic@mf.uns.ac.rs
Received: February 28, 2021
Peer-review started: February 28, 2021
First decision: September 2, 2021
Revised: September 16, 2021
Accepted: December 11, 2021
Article in press: December 11, 2021
Published online: January 24, 2022
Core Tip

Core Tip: Renal cell cancer is a highly immunogenic tumor infiltrated by cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved (immunotherapy and immunotherapy/tyrosine kinase inhibitors) as first-line treatment for metastatic clear cell renal cell cancer.